Bioventus Inc BVS.OQ BVS.O is expected to show a fall in quarterly revenue when it reports results on May 6 for the period ending March 31 2025
The Durham North Carolina-based company is expected to report a 5.2% decrease in revenue to $122.7 million from $129.46 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Bioventus Inc is for earnings of 2 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bioventus Inc is $15.00, above its last closing price of $7.26.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.08
0.15
Beat
80
Sep. 30 2024
0.01
0.03
0.06
Beat
100
Jun. 30 2024
0.07
0.07
0.19
Beat
185
Mar. 31 2024
-0.06
-0.07
0.07
Beat
193.3
Dec. 31 2023
0.05
0.02
0.07
Beat
250
Sep. 30 2023
-0.02
-0.02
0.05
Beat
350
Jun. 30 2023
0.01
0.00
0.14
Beat
Mar. 31 2023
-0.15
-0.15
-0.26
Missed
-73.3
This summary was machine generated May 2 at 14:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)